Your browser doesn't support javascript.
loading
Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities.
Amorim, Ricardo; Soares, Pedro; Chavarria, Daniel; Benfeito, Sofia; Cagide, Fernando; Teixeira, José; Oliveira, Paulo J; Borges, Fernanda.
Afiliação
  • Amorim R; CNC-UC, Center for Neuroscience and Cell Biology, University of Coimbra, Portugal; CIBB, Centre for Innovative Biomedicine and Biotechnology, University of Coimbra, Portugal.
  • Soares P; CIQUP-IMS/Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Porto, Portugal.
  • Chavarria D; CIQUP-IMS/Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Porto, Portugal.
  • Benfeito S; CIQUP-IMS/Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Porto, Portugal.
  • Cagide F; CIQUP-IMS/Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Porto, Portugal.
  • Teixeira J; CNC-UC, Center for Neuroscience and Cell Biology, University of Coimbra, Portugal; CIBB, Centre for Innovative Biomedicine and Biotechnology, University of Coimbra, Portugal.
  • Oliveira PJ; CNC-UC, Center for Neuroscience and Cell Biology, University of Coimbra, Portugal; CIBB, Centre for Innovative Biomedicine and Biotechnology, University of Coimbra, Portugal. Electronic address: pauloliv@cnc.uc.pt.
  • Borges F; CIQUP-IMS/Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Porto, Portugal. Electronic address: fborges@fc.up.pt.
Eur J Med Chem ; 277: 116723, 2024 Nov 05.
Article em En | MEDLINE | ID: mdl-39163775
ABSTRACT
Non-alcoholic fatty liver disease (NAFLD) presents a pervasive global pandemic, affecting approximately 25 % of the world's population. This grave health issue not only demands urgent attention but also stands as a significant economic concern on a global scale. The genesis of NAFLD can be primarily attributed to unhealthy dietary habits and a sedentary lifestyle, albeit certain genetic factors have also been recorded to contribute to its occurrence. NAFLD is characterized by fat accumulation in more than 5 % of hepatocytes according to histological analysis, or >5.6 % of lipid volume fraction in total liver weight in patients. The pathophysiology of NAFLD/non-alcoholic steatohepatitis (NASH) is multifactorial and the mechanisms underlying the progression to advanced forms remain unclear, thereby representing a challenge to disease therapy. Despite the substantial efforts from the scientific community and the large number of pre-clinical and clinical trials performed so far, only one drug was approved by the Food and Drug Administration (FDA) to treat NAFLD/NASH specifically. This review provides an overview of available information concerning emerging molecular targets and drug candidates tested in clinical studies for the treatment of NAFLD/NASH. Improving our understanding of NAFLD pathophysiology and pharmacotherapy is crucial not only to explore new molecular targets, but also to potentiate drug discovery programs to develop new therapeutic strategies. This knowledge endeavours scientific efforts to reduce the time for achieving a specific and effective drug for NAFLD or NASH management and improve patients' quality of life.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Descoberta de Drogas / Hepatopatia Gordurosa não Alcoólica Limite: Animals / Humans Idioma: En Revista: Eur J Med Chem Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Portugal País de publicação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Descoberta de Drogas / Hepatopatia Gordurosa não Alcoólica Limite: Animals / Humans Idioma: En Revista: Eur J Med Chem Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Portugal País de publicação: França